Yahoo · Oct 20, 2026
Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?
PBYI raised its 2026 Nerlynx sales outlook after 3.5% first-half 2026 growth, with Q3 revenues expected to reach $54-$56 million.
PB
NASDAQ · PBYI
Puma Biotechnology, Inc.
Healthcare · Biotechnology
$10.22
Up+$0.47 (+4.60%)
Updated Nov 5, 2026, 1:31 AM
SID Score
6.9/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 288.74M
- P/E ratio
- 7.8
- Dividend yield
- 0.00%
- 52-week range
- $5.85 – $11.50
- Volume
- 406.92K
- Avg. volume
- 523.37K
Price performance · PBYI
PBYI price history
1M range · 0 trading sessions · Daily adjusted prices
PBYI does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest PBYI news
The latest Smart Investors Daily articles mentioning PBYI.
Stock researchCompany · Overview
Company
Market Activity
Research & News
PBYI research
Overview
Company profile and research snapshot.
Company profile
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 7, 2026 | TD Cowen | Hold | — |
| Feb 28, 2025 | HC Wainwright & Co. | Buy | — |
| Dec 23, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 20, 2024 | HC Wainwright & Co. | Buy | — |
| Nov 8, 2024 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Oct 19, 2026
The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology
AstraZeneca, Roche, Puma Biotechnology and Olema Oncology offer breast cancer treatment opportunities, with drug sales growth, pipeline advances and clinical milestones shaping prospects.
Yahoo · Oct 16, 2026
4 Breast Cancer Stocks to Watch During Breast Cancer Awareness Month
AZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.
Benzinga · Oct 12, 2026
Puma Biotechnology Reports Q2 2026 Results: Full Earnings Call Transcript
On Thursday, Puma Biotechnology (NASDAQ:PBYI) discussed second-quarter financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
